Sedative, hypnotic or anxiolytic dependence with withdrawal
ICD-10 F13.23 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic dependence with withdrawal.
F13.23 refers to a condition characterized by a psychological and physical dependence on sedative, hypnotic, or anxiolytic substances, accompanied by withdrawal symptoms upon cessation or reduction of use. These substances include benzodiazepines, barbiturates, and other medications that depress the central nervous system. Dependence is marked by a compulsive pattern of use, tolerance, and the experience of withdrawal symptoms such as anxiety, tremors, insomnia, and seizures when the substance is not available. The diagnosis requires a thorough assessment of the patient's history, including the duration and amount of substance use, the presence of withdrawal symptoms, and the impact on daily functioning. Treatment often involves a gradual tapering of the substance, supportive care, and may include pharmacotherapy to manage withdrawal symptoms. Behavioral therapies and counseling are also critical components of a comprehensive treatment plan aimed at achieving long-term recovery.
Comprehensive mental health assessment, including history of substance use and withdrawal symptoms.
Patients presenting with anxiety disorders who have a history of benzodiazepine use.
Documenting co-occurring mental health disorders and their treatment.
Detailed treatment plans, including tapering schedules and supportive therapies.
Patients undergoing detoxification from sedatives or anxiolytics.
Coordination of care with mental health providers and monitoring for withdrawal symptoms.
Used when assessing a patient for sedative dependence.
Complete mental health evaluation and history of substance use.
Psychiatric evaluations must include substance use history.
Key symptoms include anxiety, tremors, insomnia, seizures, and in severe cases, delirium. These symptoms can vary in intensity based on the duration and amount of substance use.
